Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

M. Belickova, J. Vesela, A. Jonasova, B. Pejsova, H. Votavova, MD. Merkerova, Z. Zemanova, J. Brezinova, D. Mikulenkova, M. Lauermannova, J. Valka, K. Michalova, R. Neuwirtova, J. Cermak,

. 2016 ; 7 (24) : 36266-36279.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18017260

Grant support
NT14539 MZ0 CEP Register
NT14174 MZ0 CEP Register
NT14377 MZ0 CEP Register
NT13899 MZ0 CEP Register

TP53 mutations are frequently detected in patients with higher-risk myelodysplastic syndromes (MDS); however, the clinical impact of these mutations on the disease course of patients with lower-risk MDS is unclear. In this study of 154 lower-risk MDS patients, TP53 mutations were identified in 13% of patients, with prevalence in patients with del(5q) (23.6%) compared to non-del(5q) (3.8%). Two-thirds of the mutations were detected at the time of diagnosis, and one-third were detected during the course of the disease. Multivariate analysis demonstrated that a TP53 mutation was the strongest independent prognostic factor for overall survival (OS) (HR: 4.39) and progression-free survival (PFS) (HR: 3.74). Evaluation of OS determined a TP53 variant allele frequency (VAF) threshold of 6% as an optimal cut-off for patient stratification. The median OS was 43.5 months in patients with mutations detected at the time of diagnosis and a mutational burden of > 6% VAF compared to 138 months (HR 12.2; p = 0.003) in patients without mutations; similarly, the median PFS was 20.2 months versus 116.6 months (HR 79.5; p < 0.0001). In contrast, patients with a mutational burden of < 6% VAF were stable for long periods without progression and had no significant impact on PFS or OS. Additionally, we found a high correlation in the mutational data from cells of the peripheral blood and those of the bone marrow, indicating that peripheral blood is a reliable source for mutation monitoring. Our results indicate that the clinical impact of TP53 mutations in lower-risk MDS patients depends on the level of mutational burden.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017260
003      
CZ-PrNML
005      
20191025091523.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.9200 $2 doi
035    __
$a (PubMed)27167113
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Beličková, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0099634
245    10
$a TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes / $c M. Belickova, J. Vesela, A. Jonasova, B. Pejsova, H. Votavova, MD. Merkerova, Z. Zemanova, J. Brezinova, D. Mikulenkova, M. Lauermannova, J. Valka, K. Michalova, R. Neuwirtova, J. Cermak,
520    9_
$a TP53 mutations are frequently detected in patients with higher-risk myelodysplastic syndromes (MDS); however, the clinical impact of these mutations on the disease course of patients with lower-risk MDS is unclear. In this study of 154 lower-risk MDS patients, TP53 mutations were identified in 13% of patients, with prevalence in patients with del(5q) (23.6%) compared to non-del(5q) (3.8%). Two-thirds of the mutations were detected at the time of diagnosis, and one-third were detected during the course of the disease. Multivariate analysis demonstrated that a TP53 mutation was the strongest independent prognostic factor for overall survival (OS) (HR: 4.39) and progression-free survival (PFS) (HR: 3.74). Evaluation of OS determined a TP53 variant allele frequency (VAF) threshold of 6% as an optimal cut-off for patient stratification. The median OS was 43.5 months in patients with mutations detected at the time of diagnosis and a mutational burden of > 6% VAF compared to 138 months (HR 12.2; p = 0.003) in patients without mutations; similarly, the median PFS was 20.2 months versus 116.6 months (HR 79.5; p < 0.0001). In contrast, patients with a mutational burden of < 6% VAF were stable for long periods without progression and had no significant impact on PFS or OS. Additionally, we found a high correlation in the mutational data from cells of the peripheral blood and those of the bone marrow, indicating that peripheral blood is a reliable source for mutation monitoring. Our results indicate that the clinical impact of TP53 mutations in lower-risk MDS patients depends on the level of mutational burden.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a alely $7 D000483
650    12
$a chromozomální delece $7 D002872
650    _2
$a lidské chromozomy, pár 5 $x genetika $7 D002895
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    12
$a mutace $7 D009154
650    _2
$a myelodysplastické syndromy $x genetika $7 D009190
650    _2
$a prognóza $7 D011379
650    _2
$a rizikové faktory $7 D012307
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Veselá, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0209625
700    1_
$a Jonášová, Anna $u First Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0103767
700    1_
$a Pejsova, Barbora $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Votavová, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0081900
700    1_
$a Dostálová, Michaela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0164071
700    1_
$a Zemanová, Zuzana, $u Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1962- $7 nlk20050170627
700    1_
$a Březinová, Jana, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1958- $7 xx0046958
700    1_
$a Mikulenková, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0182877
700    1_
$a Lauermannová, Marie, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1970- $7 xx0235991
700    1_
$a Válka, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0230986
700    1_
$a Michalová, Kyra, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1942- $7 nlk19990073558
700    1_
$a Neuwirtová, Radana, $u First Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1927- $7 jk01090111
700    1_
$a Čermák, Jaroslav, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1954- $7 xx0053072
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 24 (2016), s. 36266-36279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27167113 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20191025091958 $b ABA008
999    __
$a ok $b bmc $g 1300884 $s 1014100
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 24 $d 36266-36279 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NT14539 $p MZ0
GRA    __
$a NT14174 $p MZ0
GRA    __
$a NT14377 $p MZ0
GRA    __
$a NT13899 $p MZ0
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options